What is the dosage of Enhertu?

Enhertu is available in 1 dosages, including 100 mg Injection

What does Enhertu treat?

Enhertu treats Breast Neoplasms and Gastrointestinal Neoplasms

What is Enhertu made of?

Enhertu contains trastuzumab which is a HER2/neu Receptor Antagonist

How is Enhertu administered?

Enhertu is administered as a Injectable

What is Enhertu mechanism of action?

Enhertu mechanism of action is HER2/Neu/cerbB2 Antagonists

Dosage & Administration Biomarker testing Drug label Prior authorization Pharmacy Financial assistance

Patient education People also ask

Enhertu

(trastuzumab)

fam-trastuzumab deruxtecan-nxki 100 MG Injection [Enhertu]

BLACK BOX WARNING

Dosage & administration

* Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine.
* For intravenous infusion only. Do not administer as an intravenous push or bolus. DO NOT use Sodium Chloride Injection, USP.
* Premedicate for prevention of chemotherapy-induced nausea and vomiting.
* The recommended dosage of ENHERTU for breast cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
* The recommended dosage of ENHERTU for lung cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
* The recommended dosage of ENHERTU for gastric cancer is 6.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
* Management of adverse reactions (ILD, neutropenia, thrombocytopenia, or left ventricular dysfunction) may require temporary interruption, dose reduction, or discontinuation of ENHERTU.

biomarker testing

Enhertu clinical details

Genetic testing requirements were obtained from the NCCN guidelines for each cancer type.

drug label

Enhertu prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Enhertu prior authorization resources

Most recent Enhertu prior authorization forms

View By Payer

Updated: May 30, 2023Cigna - Enhertu Prior Authorization Form

Updated: May 24, 2023Aetna - Enhertu Prior Authorization Form

Updated: May 23, 2023Aetna - Medicare Part B Enhertu Prior Authorization Form

OTHERComplete Letter of Medical Necessity

OTHERCoverage Authorization Appeals

PDFEnhertu PA Checklist

Learn More

Benefits investigation

PDFEnhertu4u Enrollment Form

PDFEnhertu4u Enrollment Form - Spanish

Learn More

pharmacy

Enhertu preferred pharmacy

OTHERPharmacy List

financial assistance

Enhertu financial assistance options

Co-pay savings program

commercial only

PDFEnhertu4u Enrollment Form

PDFEnhertu4u Enrollment Form - Spanish

OTHEREnroll in Patient Savings Program

Enroll in Patient Savings Program - HCP Office Online Portal

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDFPatient Assistance Program Enrollment Form - English

PDFPatient Assistance Program Enrollment Form - Spanish

Independent Financial Support Programs

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.